CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Kuromanin chloride (Chrysontemin chloride) is potent antioxidants and free radical scavengers, may act as modulators of gene regulation and signal transduction pathways.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

Ara-F-NAD+ sodium, an arabino analogue of NAD+, serves as a potent, reversible, and slow-binding inhibitor of the CD38 NADase [1] [2].

CD38 inhibitor 2 is an effective CD38 inhibitor (IC50 = 10–100 nM) suitable for cancer and immunology research.

Ara-F-NAD+, an arabino analogue of NAD + , is a potent, slow-binding CD38 NADase inhibitor, with a K i of 169 nM.

CD38-IN-5 (compound 1) is a CD38 inhibitor that selectively inhibits CD38 hydrolase with an IC50 of 4.0 μM but does not inhibit CD38 cyclase. It effectively enhances NK cell-mediated tumor cytotoxicity and increases NADH+ and IFNγ levels in activated peripheral blood mononuclear cells (PBMC). CD38-IN-5 is applicable in cancer research.

SAR442257 is a humanized IgG4-S228P (κ type) monoclonal antibody designed to target CD38 on the surface of multiple myeloma cells, while also co-stimulating CD3 and CD28 molecules on T cells.

Anti-Mouse CD38 Antibody (NIMR5) is a mouse-specific IgG2a monoclonal antibody targeting CD38 that activates ERK signaling, promotes apoptosis, restores T-cell function, upregulates CD1d expression, and enhances spleen cell proliferation as well as dendritic cell and natural killer T cell expansion, thereby providing a versatile immunological tool for mechanistic studies in cancer and immuno-oncology research, including melanoma and colon cancer models.

6-Alkyne-F-araNAD is an irreversible CD38 inhibitor that aids in better visualization of intracellular CD38 localization when used alongside other fluorescent probes (such as SR101−F-araNMN).

Erzotabart is an IgG1-kappa monoclonal antibody that targets human CD38 (also known as ADP-ribosyl cyclase 1 or cyclic ADP-ribose hydrolase 1) and displays pronounced antineoplastic activity. Erzotabart acts by modulating CD38-mediated signaling pathways involved in tumor cell metabolism, proliferation, and immune evasion, making it a significant investigational candidate in oncology research.

CVN14 is an efficient and selective CD38 inhibitor that can penetrate the blood-brain barrier, with an IC50 of 19 nM in humans and 2.4 nM in mice. It binds non-competitively with CD38 and ADPR to form a complex, thereby inhibiting CD38 enzyme activity. CVN14 is applicable for research into neurodegenerative diseases.

AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 and CD3E. It effectively kills cancer cells that express CD38, stimulates T cell proliferation, and reduces cytokine release. AMG-424 exhibits antitumor activity in mouse cancer models with bone marrow invasion and induces peripheral B cell depletion in cynomolgus monkeys. It is used in studies of multiple myeloma. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3.

GBR-1342 is a human bispecific antibody targeting CD38 and CD3. It inhibits the activity of cancer cell lines Daudi, RAJI, RPMI8226, IM-9, and NCI-H929, and is applicable to multiple myeloma research.

Anti-Human-CD38 Antibody (Daratumumab hexabody) is an antibody. Its expression system is HEK293 cells, and the isotype control is IgG1, Kappa.

NOTA-MK0159 is a conjugate of NOTA and MK0159. It inhibits CD38 in both humans and mice, with IC50 values of 72.58 nM and 7.55 nM, respectively. When radiolabeled, NOTA-MK0159 functions as an imaging agent with specific uptake in CD38-positive multiple myeloma cells, enabling non-invasive systemic evaluation of CD38 expression in multiple myeloma xenografts. NOTA-MK0159 is applicable for research in multiple myeloma.

Lumrotatug is a human-derived IgG1κ monoclonal antibody designed to target CD38. The isotype control for Lumrotatug is HumanIgG1kappa, Isotype Control.